Federal Register / Vol. 69, No. 185 / Friday, September 24, 2004 / Notices 57335

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, ZRG1 SBIB 

R 15B: Small Business: Ultrasound. 

Date: October 19, 2004. 

Time: 1:30 p.m. to 2:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Hector Lopez, DSC, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5120, 

MSC 7854, Bethesda, MD 20892, (301) 435–

2392, lopezh@csr.nih.gov.

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Program 

Project in Cell Biology. 

Date: October 21–22, 2004. 

Time: 6 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The River Inn, 924 25th Street, NW., 

Washington, DC 20037. 

Contact Person: Alexandra M. Ainsztein, 

PhD, Scientific Review Administrator, Center 

for Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5144, 

MSC 7840, Bethesda, MD 20892, (301) 451–

3848, ainsztea@csr.nih.gov.

Name of Committee: Musculoskeletal, Oral 

and Skin Sciences Integrated Review Group, 

Skeletal Biology Structures and Regeneration 

Study Section. 

Date: October 25–26, 2004. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Holiday Inn Chevy Chase, 5520 

Wisconsin Avenue, Chevy Chase, MD 20815.

Contact Person: Mehrdad M. Tondravi, 

PhD, Scientific Review Administrator, Center 

for Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4108, 

MSC 7814, Bethesda, MD 20892, (301) 435–

1173, tondravm@csr.nih.gov.

Name of Committee: Infectious Diseases 

and Microbiology Integrated Review Group, 

Prokaryotic Cell and Molecular Biology 

Study Section. 

Date: October 26–27, 2004. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: St. Gregory Hotel, 2003 M Street, 

NW., Washington, DC 20036. 

Contact Person: Diane L. Stassi, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3202, 

MSC 7808, Bethesda, MD 20892, (301) 435–

2514, stassid@csr.nih.gov.

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Physiology 

and Pathobiology of the Organ Systems. 

Date: October 26–27, 2004. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Courtyard by Marriott, 1600 Rhode 

Island Avenue, Washington, DC 20036. 

Contact Person: Peter J. Perrin, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 2183, 

MSC 7818, Bethesda, MD 20892, (301) 435–

0682, perrinp@csr.nih.gov.

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, SBMI 11: 

Small Business Imaging: Optical and Video. 

Date: October 26, 2004. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Holiday Inn Select Bethesda, 8120 

Wisconsin Ave., Bethesda, MD 20814. 

Contact Person: Robert J. Nordstrom, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5118, 

MSC 7854, Bethesda, MD 20892, (301) 435–

1175, nordstrr@csr.nih.gov.

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, SBMI 10: 

Small Business Medical Imaging: PET/MRI/

X-ray. 

Date: October 27, 2004. 

Time:8 a.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Holiday Inn Select Bethesda, 8120 

Wisconsin Ave., Bethesda, MD 20814. 

Contact Person: Robert J. Nordstrom, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5118, 

MSC 7854, Bethesda, MD 20892, (301) 435–

1175, nordstrr@csr.nih.gov.

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Cancer 

Immunopathology and Immunotherapy (CII). 

Date: October 27–28, 2004. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Churchill Hotel, 1914 Connecticut 

Avenue, NW., Washington, DC 20009. 

Contact Person: Marcia Litwack, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6206, 

MSC 7804, Bethesda, MD 20892, (301) 435–

1719.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93,337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS)

Dated: September 17, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–21448 Filed 9–23–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of PartiallyExclusive Licenses: Human-Bovine 

Reassortant Rotavirus Vaccine

AGENCY: National Institutes of Health, 

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

404.7(a)(1)(i), that the National 

Institutes of Health (NIH), Department 

of Health and Human Services, is 

contemplating the grant of partially 

exclusive licenses in (1) India; (2) 

China; and (3) Brazil to practice the 

invention embodied in U.S. Serial 

Number 60/094,425, filed July 28, 1998, 

PCT filed (PCT/US99/17036) on July 27, 

1999, and National Stage filed in China, 

India, Korea, Australia, Canada, Europe, 

Japan, Brazil and the U.S., entitled 

‘‘Multivalent Human-Bovine Rotavirus 

Vaccine’’ (DHHS ref. E–015–1998/0) as 

follows: (1) Co-exclusive licenses in 

India only to Biological E LTD, having 

a place of business in Hyderabad, India, 

and Bharat Biotech International LTD, 

having a place of business in 

Hyderabad, India; (2) non-exclusive 

licenses exclusively offered to 

companies and/or institutions within 

China; and (3) exclusive license in 

Brazil only to Fundacao Instituto 

Butantan, having a place of business in 

Sao Paolo, Brazil. The patent rights in 

these inventions have been assigned to 

the Government of the United States of 

America.

DATES: Only written comments and/or 

application for a license which are 

received by the NIH Office of 

Technology Transfer on or before 

December 23, 2004 will be considered.

ADDRESSES: Requests for a copy of the 

patent application, inquiries, comments 

and other materials relating to the 

contemplated license should be directed 

to: Susan Ano, Office of Technology 

Transfer, National Institutes of Health, 

6011 Executive Boulevard, Suite 325, 

Rockville, MD 20852–3804; E-mail: 

anos@od.nih.gov; Telephone: (301) 435–

5515; Facsimile: (301) 402–0220.

SUPPLEMENTARY INFORMATION: The 

technology embodied in the above 

patent rights involves multivalent 

immunogenic compositions comprising 

at least four human-bovine reassortant 

rotaviruses, where the gene encoding 

VP7 protein from G1, G2, G3, or G4 

human rotavirus strain is inserted into 

a bovine rotavirus backbone. These VP7 

serotypes represent the clinically most 

important human rotavirus serotypes, 

which depends on VP4 and VP7 

proteins, both found in the viral capsid 

and both of which independently 

induce neutralizing antibodies. 

Additionally, human-bovine 

reassortants for VP7 serotypes G5 and 

G9 and a bovine-bovine reassortant for 

VP7 G10 serotype are mentioned. Each 

of these reassortants is monovalent, and 

57336 Federal Register / Vol. 69, No. 185 / Friday, September 24, 2004 / Notices 

administered as a multivalent mixture. 

Compared to other human-bovine 

rotavirus reassortants, the compositions 

described in this technology induce an 

immunological response at significantly 

lower dosage than other human-bovine 

rotavirus reassortants (which required 

10–100 times the dose of human-rhesus 

reassortants) and does not result in a 

low-grade, transient fever. 

The prospective partially exclusive 

licenses will be royalty bearing and will 

comply with the terms and conditions 

of 35 U.S.C. 209 and 37 CFR 404.7. The 

prospective partially exclusive licenses 

may be granted unless, within 90 days 

from the date of this published Notice, 

NIH receives written evidence and 

argument that establishes that the grant 

of the license would not be consistent 

with the requirements of 35 U.S.C. 209 

and 37 CFR 404.7. 

The field of use may be limited to 

development of human-bovine 

reassortant rotavirus vaccines. 

The licensed territory will be 

exclusive as outlined above and 

excluding U.S., Europe, and Canada. 

Properly filed competing applications 

for a license filed in response to this 

notice will be treated as objections to 

the contemplated license. Comments 

and objections submitted in response to 

this notice will not be made available 

for public inspection, and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552.

Dated: September 17, 2004. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health.

[FR Doc. 04–21426 Filed 9–23–04; 8:45 am] 

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Complementary 

and Alternative Medicine 

Announcement of Draft 5-Year 

Strategic Plan

ACTION: Notice.

SUMMARY: The National Center for 

Complementary and Alternative 

Medicine (NCCAM) is developing its 5-

year strategic plan (2005–2009), and 

invites the public to provide comments 

on a draft of this plan. The draft plan 

will be publicly available through the 

NCCAM Web site at http://

nccam.nih.gov from on or about October 

4 through November 15, 2004. The 

public is invited to provide comments 

through the mail and via the NCCAM 

Web site. 

Background 

The National Center for 

Complementary and Alternative 

Medicine (NCCAM) was established in 

1998 with the mission of exploring 

complementary and alternative healing 

practices in the context of rigorous 

science, training CAM researchers, and 

disseminating authoritative information 

to the public and professionals. 

To date, NCCAM’s efforts to 

rigorously study CAM, to train CAM 

researchers, to conduct outreach, and to 

facilitate integration have been guided 

by NCCAM’s current strategic plan, 

‘‘Expanding Horizons of Healthcare: 

Five Year Strategic Plan 2001–2005’’

located on the NCCAM Web site at 

http://nccam.nih.gov/about/plans/

fiveyear/index.htm. Since its inception, 

NCCAM has funded over 800 research 

projects and has over 700 grantee 

publications. 

NCCAM’s new strategic plan will 

stipulate strategic goals and will outline 

a research agenda for CAM domains and 

scientific areas, based on identified 

needs and opportunities. 

The public is invited to review the 

draft strategic plan and provide 

comments from October 4 through 

November 15, 2004. The draft plan may 

be viewed at http://nccam.nih.gov/. 

Hard copies of the plan may be obtained 

by calling 1–888–644–6226 or by emailing to info@nccam.nih.gov. 

Request for Comments 

The public is invited to provide 

comments on the draft strategic plan for 

2005–2009. Comments may be provided 

through the NCCAM Web site at

http://nccam.nih.gov or via U.S. mail to: 

Strategic Plan Feedback, National 

Center for Complementary and 

Alternative Medicine, NIH, 31 Center 

Drive, MSC 2182, Bethesda, MD 20892–

2182.

FOR FURTHER INFORMATION: To request 

more information, visit the NCCAM 

Web site at http://nccam.nih.gov, call 1–

888–644–6226, or e-mail 

info@nccam.nih.gov. 

Comments Due Date 

Comments regarding the draft of 

NCCAM’s strategic plan are best assured 

of having their full effect if received by 

November 15, 2004.

Dated: September 15, 2004. 

Christy Thomsen, 

Director, Office of Communications and 

Public Liaison, National Center for 

Complementary and Alternative Medicine, 

National Institutes of Health.

[FR Doc. 04–21427 Filed 9–23–04; 8:45 am] 

BILLING CODE 4140–01–P

DEPARTMENT OF HOMELAND 

SECURITY 

Coast Guard 

[USCG–2004–19167] 

Statutory Monetary Civil Penalty 

Increase for Bridge Violations

AGENCY: Coast Guard, DHS.

ACTION: Notice.

SUMMARY: This notice is to inform the 

public that on August 9, 2004, President 

Bush signed the Coast Guard and 

Maritime Transportation Act of 2004 

which, in part, increases the monetary 

civil penalty amount the Coast Guard 

can levy for a violation of bridge 

regulations and statutes.

FOR FURTHER INFORMATION CONTACT: If 

you have questions on this notice, call 

Chris Jaufmann, Coast Guard, telephone 

202–267–0368.

SUPPLEMENTARY INFORMATION: 33 U.S.C 

495(b), 499(c), 502(c), and 533(b), 

authorizes assessing penalties for 

violations of bridge regulations found in 

33 CFR parts 115, 116, 117, and 118. 

The maximum penalty amount that 

could be levied per bridge violation per 

day was $1,000. In 1997, the maximum 

penalty amount was raised to $1,100 to 

adjust for inflation. 

On August 9, 2004 President Bush 

signed the Coast Guard and Maritime 

Transportation Act of 2004 into law. 

(Pub. L. 108–293) section 601 of this act, 

raises the maximum civil penalty 

amount that the Coast Guard can levy 

per bridge violation per day from $1,100 

to $5000 for the remainder of 2004. The 

Act then raises that amount by $5000 

increments at the start of each calendar 

year until 2008 when the maximum 

amount allowed per violation per day 

will be $25,000. Thus, the penalty is 

$5,000 for a violation occurring in 2004; 

$10,000 for a violation occurring in 

2005; $15,000 for a violation occurring 

in 2006; $20,000 for a violation 

occurring in 2007; and $25,000 for a 

violation occurring in 2008 and every 

year after that. This increase took effect 

immediately upon signature.